What is GMP compliance and why does it matter?

GMP compliance means following Good Manufacturing Practice regulations that govern how pharmaceutical products, biologics, and medical devices are manufactured, tested, and controlled. These rules exist to ensure that every product reaching a patient is consistently safe, effective, and of the quality it claims to be. The sections below unpack the principles, regulatory expectations, consequences of failure, and practical steps companies take to stay compliant.

What are the core principles behind GMP compliance?

GMP compliance is built on the idea that quality cannot be tested into a product after the fact — it must be designed and built in at every stage of manufacturing. The core principles cover people, processes, premises, equipment, and documentation, ensuring that manufacturing outcomes are predictable, traceable, and reproducible.

The foundational pillars of GMP compliance include:

• Quality management systems: A documented framework that defines responsibilities, procedures, and controls across the entire manufacturing operation.
• Personnel qualification: Everyone involved in manufacturing must be trained for their role, and that training must be documented.
• Premises and equipment: Facilities must be designed to prevent contamination and mix-ups, and equipment must be qualified and regularly maintained.
• Process validation: Manufacturing processes must be proven to consistently produce a product meeting its specifications before commercial release.
• Documentation and traceability: Every action, test result, and deviation must be recorded so that any batch can be fully reconstructed from paper or electronic records.
• Change control: Any change to a process, material, or system must be assessed, approved, and documented before implementation.

These principles apply whether a company is manufacturing a small-molecule tablet or a complex biologic. The spirit of GMP is continuous assurance — not a one-time checkbox exercise.

Which regulatory bodies set GMP requirements?

GMP requirements are set by national and regional regulatory authorities, each with jurisdiction over products marketed or manufactured within their territory. The most influential bodies are the European Medicines Agency (EMA) and national competent authorities in the EU, the US Food and Drug Administration (FDA), and the World Health Organization (WHO), whose guidelines are widely adopted in markets without their own detailed GMP frameworks.

In the European Union, GMP requirements for medicinal products are laid out in EudraLex Volume 4, which covers both human and veterinary medicines and is enforced by national competent authorities such as the Dutch MEB (CBG) or Germany’s BfArM. The FDA publishes its GMP expectations through 21 CFR Parts 210 and 211 for pharmaceuticals and 21 CFR Part 820 for medical devices. The International Council for Harmonisation (ICH) also plays a central coordinating role, producing guidelines like ICH Q7, Q10, and Q11 that are adopted across multiple regions.

For medical devices specifically, the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) set quality system requirements that align closely with ISO 13485, the internationally recognized quality management standard for medical device manufacturers.

What happens when a company fails GMP compliance?

When a company fails GMP compliance, the consequences range from regulatory observations and warning letters to product recalls, manufacturing shutdowns, and ultimately the loss of marketing authorization. The severity of the outcome depends on the nature and scale of the deficiency found.

Regulatory inspectors classify findings by risk level. Critical deficiencies — those that pose an immediate risk to patient safety or data integrity — can trigger immediate action, including suspension of a manufacturing license or an import ban. Major deficiencies require a corrective action plan within a defined timeframe, while other observations are typically addressed in a post-inspection response. Repeated or unresolved findings escalate quickly.

Beyond regulatory penalties, GMP failures carry significant business consequences. A single product recall can cost a company millions and damage supplier and customer relationships that took years to build. In highly regulated markets like the EU and US, a manufacturing site placed on an import alert or receiving a public warning letter faces reputational damage that affects future partnerships, investor confidence, and market access. The cost of non-compliance almost always exceeds the cost of maintaining a robust GMP system.

How does GMP compliance differ for biologics and medical devices?

GMP compliance for biologics and medical devices follows the same underlying quality principles but applies them to fundamentally different product types, manufacturing processes, and regulatory frameworks. Biologics face stricter process control requirements because living systems are inherently variable, while medical devices are governed by quality system regulations that emphasize design controls and post-market surveillance.

GMP for biologics

Biologics — including monoclonal antibodies, vaccines, cell therapies, and gene therapies — are produced using living cells, which means the process itself defines the product. A change in cell culture conditions, raw material quality, or purification steps can alter the product’s safety and efficacy profile. GMP for biologics therefore places exceptional emphasis on process validation, raw material controls, environmental monitoring, and comparability studies when changes are made. Specific guidance such as ICH Q5A to Q5E and the EMA’s guidelines on biologics manufacturing set detailed expectations in this area.

GMP for medical devices

Medical devices are regulated under quality management system requirements rather than traditional pharmaceutical GMP. In the EU, ISO 13485 provides the framework, and compliance with it is a prerequisite for CE marking under the MDR and IVDR. The focus shifts toward design and development controls, risk management (ISO 14971), usability engineering, and post-market clinical follow-up. For drug-device combination products, both pharmaceutical GMP and device quality system requirements apply, which creates an additional layer of regulatory complexity that requires careful planning from the outset.

How do companies prepare for a GMP inspection?

Companies prepare for a GMP inspection by conducting a systematic review of their quality management system, documentation, processes, and facilities to identify and close any gaps before an inspector does. Effective preparation is not a last-minute effort — it is an ongoing program of internal audits, mock inspections, and continuous improvement.

Key preparation steps include:

1. Internal audits: Schedule regular audits against the applicable GMP guidelines and quality standards to identify deviations before they become inspection findings.
2. Mock inspections: Simulate a regulatory inspection with an experienced auditor who can challenge your team and test your document retrieval and response processes.
3. CAPA review: Ensure all open corrective and preventive actions are on track and that previously identified issues have been fully resolved with evidence.
4. Documentation readiness: Confirm that batch records, validation reports, deviation logs, and training records are complete, current, and readily accessible.
5. Staff preparation: Brief relevant personnel on inspection etiquette, their specific roles, and how to respond accurately and confidently to inspector questions.
6. Facility walkthrough: Inspect production areas, laboratories, and storage conditions with fresh eyes to catch housekeeping issues, equipment status, and labeling that might draw attention.

Companies that treat GMP compliance as a continuous operational standard — rather than a periodic inspection exercise — consistently perform better during regulatory visits and resolve findings more efficiently. To learn more about how a structured approach to quality can support your operations, visit our services overview.

When should a company bring in external GMP expertise?

A company should bring in external GMP expertise when internal resources lack the specific knowledge required, when an inspection or audit has revealed significant gaps, or when a new product type, market, or regulatory requirement falls outside the team’s existing experience. External expertise is also valuable during periods of rapid growth, organizational change, or when preparing for a first-time inspection in a new jurisdiction.

Common triggers for seeking external GMP support include:

• Preparing for an EMA, FDA, or national competent authority inspection with limited prior experience of that authority’s expectations
• Receiving a warning letter or critical inspection finding that requires a credible, independent corrective action plan
• Expanding into biologics, ATMPs, or combination products where GMP requirements are more complex than for standard small molecules
• Implementing a new quality management system or transitioning to electronic records under data integrity requirements
• Conducting due diligence on a manufacturing partner or acquisition target where an independent quality assessment is needed

The right moment to bring in external support is before a problem escalates, not after. Experienced GMP consultants can identify risks that internal teams — close to day-to-day operations — may overlook, and they bring direct knowledge of how regulators interpret and enforce the rules in practice. You can find out more about who we are and the expertise we bring on our company page.

How Starodub supports your GMP compliance

We work alongside biopharmaceutical and medical device companies to build and maintain GMP compliance programs that hold up under regulatory scrutiny. Our team brings hands-on experience across the full spectrum of product types — from small molecules and biologics to class III medical devices and combination products — and we understand how regulatory expectations translate into practical operational requirements.

Our GMP compliance support covers:

• Gap assessments and readiness reviews ahead of EMA, FDA, or national authority inspections
• Mock inspections and audit support to test your systems and prepare your team
• Quality management system development and improvement aligned with GxP, ISO 9001, and ISO 13485 standards
• CAPA management and deviation handling to resolve findings efficiently and prevent recurrence
• GMP support for biologics, ATMPs, and combination products where regulatory complexity is highest
• Operational improvement programs led by our Lean Six Sigma Master Black Belts, combining quality compliance with process efficiency

We keep our team lean and communication direct — you work with a single point of contact backed by collective expertise, not a chain of intermediaries. If you want to strengthen your GMP compliance position or prepare for an upcoming inspection, get in touch with us to discuss how we can support your specific situation.

Related Articles

• Can artificial intelligence improve regulatory strategy development?
• What is the role of regulatory science in strategic planning?
• What is the difference between ICH and FDA guidelines?
• What is the average time to approve a drug?
• What regulatory affairs services do medical device companies need?

This content was generated with the help of AI and it may contain mistakes